Celltrion Healthcare’s anticancer therapeutics Herzuma® (trastuzumab) and Truxima® (rituximab) win Brazilian tender for two consecutive years
Celltrion Healthcare’s anticancer therapeutics Herzuma® (trastuzumab) and Truxima® (rituximab) win Brazilian tender for two consecutive years
· Celltrion Healthcare signs exclusive contract to supply Herzuma® (trastuzumab) to the Federal Government in Brazil, which accounts for about 80 percent of Brazil's trastuzumab market
· Celltrion Healthcare’s Truxima® (rituximab) wins 8 state bids, including Sao Paulo, which is the largest of Brazil’s state bids
· The company aims to lead market position in the Central- South American biosimilar market
August 3 2021, INCHEON, KOREA – Celltrion Healthcare today announced that the company has signed a contract to supply its two anticancer therapeutics - Herzuma® (trastuzumab) and Truxima® (rituximab) to the Brazilian market. The company won the order in an open bidding held by the Ministry of Health of Federal Government of Brazil marking two consecutive years of winning the bid.
Under the contract, the company will supply Herzuma® (trastuzumab) to the public market, which accounts for approximately 80 percent of Brazil's trastuzumab market. The company has won a total of eight state bids for Truxima®(rituximab) this year, including a bid in Sao Paulo, which is the largest of Brazil's state bids.
“There is a great demand to substitute expensive original pharmaceuticals with biosimilar drugs with proven safety and efficacy to reduce health care costs in Central and South America,” said Dr. HoUng Kim, Ph.D., Head of Medical and Marketing Division at Celltrion Healthcare. “We are excited to win one of the most important bids in Brazil for two consecutive years and will continue to expand our presence in the Central and Southern American market with our anticancer biosimilar products.”
Based on its successful bid in Brazil, Celltrion Healthcare plans on expediting its market expansion into the Latin American Market. As part of these efforts, in March 2021, Celltrion Healthcare has initiated direct sales of Remsima® (infliximab) in Colombia and plans to additionally adopt the direct sales model for Truxima® (rituximab) and Herzuma® (trastuzumab) in June and July respectively. In addition, Celltrion Healthcare plans to expand its direct sales business model to Peru and Chile in the third quarter of this year.
- ENDS -
Notes to Editors:
About Herzuma® (trastuzumab)
Herzuma® is a humanised monoclonal antibody that is designed to bind selectively to the extracellular domain of an antigen called human epidermal growth factor receptor 2 (HER2). Herzuma® is indicated for the treatment of adult patients with early breast cancer, metastatic breast cancer, and metastatic gastric cancer and was approved by the European Medicines Agency (EMA) in February 2018 and the US Food and Drug Administration (FDA) in December 2018. Similarity of Herzuma® to the reference product, Herceptin® was demonstrated in terms of pharmacokinetic, pharmacodynamics, efficacy and safety through multiple global clinical trials.
About Truxima® (rituximab)[1],[2]
Truxima® is a mAb that targets CD20, a transmembrane protein found on the surface of most B-cells. By binding specifically to CD20, Truxima® depletes B-cells by three main mechanisms: induction of apoptosis, stimulation of CDC (complement-dependent cytotoxicity) and stimulation of ADCC (antibody-dependent cell-mediated cytotoxicity). Truxima® is approved in the EU and US for the treatment of patients with non-Hodgkin lymphoma (NHL), chronic lymphocytic leukaemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis and microscopic polyangiitis. Truxima® is the first rituximab similar biotherapeutic product to be prequalified by the World Health Organization (May 2020).
About Celltrion Healthcare
Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com.
[1] European Medicines Agency Summary of Product Characteristics (SmPC). Truxima. Available at https://www.ema.europa.eu/en/documents/product-information/truxima-epar-product-information_en.pdf Last accessed July 2021
[2] First rituximab similar biotherapeutic products prequalified. World Health Organization. Available at: https://extranet.who.int/prequal/news/first-rituximab-biotherapeutic-products-prequalified Last accessed July 2021